Bioxcel Therapeutics Inc (NQ: BTAI )

50.46 USD -0.91 (-1.77%)

Official Closing Price Updated: 4:52 PM EST, Jan 27, 2021 Add to My Watchlist

Price and Volume

Volume	651,262
Open	50.04
Bid (Size)	50.10 (1)
Ask (Size)	51.20 (1)
Prev. Close	51.37
Today's Range	48.86 - 54.60
52wk Range	13.77 - 71.50
Shares Outstanding	15,645,545
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease

January 05, 2021

BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 17, 2020

Performance

YTD	-3.43%	-3.43%
1 Month	-0.16%	-0.16%
3 Month	+4.93%	+4.93%
6 Month	-3.96%	-3.96%
1 Year	+190.00%	+190.00%

More News

BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD

December 07, 2020

BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

November 13, 2020

BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

November 12, 2020

BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

November 11, 2020

BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting

November 09, 2020

BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast

November 05, 2020

Implied LABU Analyst Target Price: $160

January 14, 2021

10 Biggest Price Target Changes For Wednesday

January 06, 2021

BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium

October 26, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.